Woodline Partners LP

Position in LXEO — Lexeo Therapeutics, Inc.

CIK 1784547 San Francisco, CA

Position in LXEO

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$15,788,053

-$15,965,703 QoQ

Shares Held

2,750,532

-14.0% QoQ

Ownership

3.50%

of shares outstanding

% of Portfolio

0.06%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Woodline Partners LP holds $3,424,016,489 across 189 Biotechnology names. LXEO ranks #59 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	2,506,570	$243,763,932
2	TNGX	Tango Therapeutics, Inc.	8,000,013	$167,360,271
3	PTGX	Protagonist Therapeutics, Inc	1,414,173	$149,053,834
4	QNCX	Quince Therapeutics, Inc.	5,200,000	$105,040,000
5	RCUS	Arcus Biosciences, Inc.	3,777,798	$81,600,436
6	ALNY	Alnylam Pharmaceuticals, Inc.	243,883	$80,693,568
7	SRRK	Scholar Rock Holding Corp	1,500,470	$73,763,105
8	RYTM	Rhythm Pharmaceuticals, Inc.	758,891	$66,000,750

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$15,788,053	2,750,532	-14.0%	Shares	Sole	2026-05-15
2025-12-31	$31,753,756	3,197,760	+24.3%	Shares	Sole	2026-02-17
2025-09-30	$17,079,155	2,572,162	0.0%	Shares	Sole	2025-11-14
2025-06-30	$10,340,091	2,572,162	+207.3%	Shares	Sole	2025-08-14
2025-03-31	$2,904,438	837,014	-2.5%	Shares	Sole	2025-05-15
2024-12-31	$5,650,186	858,691	+0.8%	Shares	Sole	2025-02-14
2024-09-30	$7,701,727	851,961	+3.4%	Shares	Sole	2024-11-14
2024-06-30	$13,218,146	824,074	+6738.2%	Shares	Sole	2024-08-14
2024-03-31	$188,959	12,051	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.